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Stressful life experiences are likely etiological factors in sporadic forms of Alzheimer’s disease (AD). Many AD patients hypersecrete
glucocorticoids (GCs), and their GC levels correlate with the rate of cognitive impairment and extent of neuronal atrophy. Severity of
cognitive deficits in AD correlates strongly with levels of hyperphosphorylated forms of the cytoskeletal protein TAU, an essential
mediator of the actions of amyloid  (A), another molecule with a key pathogenic role in AD. Our objective was to investigate the
sequential interrelationships between these various pathogenic elements, in particular with respect to the mechanisms through which
stress might precipitate cognitive decline. We thus examined whether stress, through the mediation of GCs, influences TAU hyperphos-
phorylation, a critical and early event in the cascade of processes leading to AD pathology. Results from healthy, wild-type, middle-aged
rats show that chronic stress and GC induce abnormal hyperphosphorylation of TAU in the hippocampus and prefrontal cortex (PFC),
with contemporaneous impairments of hippocampus- and PFC-dependent behaviors. Exogenous GC potentiated the ability of centrally
infused A to induce hyperphosphorylation of TAU epitopes associated with AD and cytoplasmic accumulation of TAU, while previous
exposure to stress aggravated the biochemical andbehavioral effects of GC inA-infused animals. Thus, lifetime stress/GC exposuremay
have a cumulative impact on the onset and progress of AD pathology, with TAU hyperphosphorylation serving to transduce the negative
effects of stress and GC on cognition.
Introduction
The etiology of late-onset, sporadic (nonfamilial) forms of Alz-
heimer’s disease (AD) is largely unknown, but there is growing
consensus that lifetime events such as environmental stressors
may increase the probability of risk for the disease (Wilson et al.,
2003; Csernansky et al., 2006; Kang et al., 2007). This view is
supported by reports of hypersecretion of stress hormones [glu-
cocorticoids (GCs)] in AD patients (Hartmann et al., 1997;
Weiner et al., 1997; Elgh et al., 2006), and indications that psy-
chological distressmay causemild cognitive impairment (Wilson
et al., 2003) and predispose affected individuals to AD (Wilson et
al., 2007). Studies in humans and animals demonstrate a robust
relationship among elevated GC secretion, cognitive impair-
ment, and neuronal atrophy. The cognition-impairing actions of
stress and high GC levels are largely ascribed to concomitant
reductions in the volume of the hippocampus (Sousa et al., 2000;
Landfield et al., 2007; Lupien et al., 2009), a brain area that dis-
plays some of the earliest neurodegenerative changes in AD.
Stress and GC induce similar volumetric reductions in the pre-
frontal cortex (PFC) (Cerqueira et al., 2007; Schubert et al.,
2008), which receives afferents from the hippocampus and is
critical for the control of higher cognitive functions.
Amyloid  (A) has a well established role in AD-associated
neuropathology, although there is evidence that cognitive deficits
are detectable in advance of A deposition into senile plaques
(Terry et al., 1991; Guillozet et al., 2003). Previous studies inmice
carrying human transgenes implicated in familial AD reported
that chronic stress and exogenous GC accelerate the production
and deposition of A and impair learning andmemory (Green et
al., 2006; Jeong et al., 2006); additionally, treatment of nontrans-
genic animals with either chronic stress or exogenous GC shifts
the metabolism of amyloid precursor protein (APP) in favor of
the amyloidogenic pathway (Catania et al., 2009). On the other
hand, the cytoskeletal protein TAUappears tomediate the patho-
genic actions of A (Rapoport et al., 2002; Roberson et al., 2007)
after its hyperphosphorylation by TAU kinases such as GSK3
and cdk5 (Takashima et al., 1998). Indeed, anomalous hyper-
phosphorylation of TAU is another pathogenic mechanism in
AD: specifically, hyperphosphorylated TAU detaches from
microtubules, oligomerizes, and accumulates in the somato-
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dendritic compartment, resulting in neuronal dystrophy and
degeneration and cognitive impairment (Grundke-Iqbal et al.,
1986; Sengupta et al., 1998; Schneider et al., 1999).
The results of the present study in nontransgenic middle-aged
rats show that stress and GCmarkedly compromise hippocampus-
dependent referencememory and PFC-dependent behavioral flexi-
bility andaggravate thebehavioral effects of central infusionsofA1-
40. These behavioral impairments occur concomitantly with
increased levels of TAU kinases and hyperphosphorylated TAU,
thus suggesting a new cellularmechanism through which stress and
GC interfere with the neurostructural correlates of behavior.
Materials andMethods
Animal procedures. Male Wistar rats, aged 14 months, were used in ac-
cordance with European Union Council Directive 86/609/EEC and local
animal welfare regulations. Animals were housed four to five per cage
under standard environmental conditions [temperature 22°C; relative
humidity 70%; 12 h light/dark cycle (lights on at 6:00 A.M.); ad libitum
access to food and water]. Subgroups (n  6–7) were subjected to 1
month of chronic, unpredictable stress (Catania et al., 2009). Briefly, the
stress paradigm involved random application of one of the following
stressors, daily: hypertonic saline [9% NaCl, i.p., 1 ml/100 g of body
weight (BW)], overcrowding for 1 h, placement in a confined environ-
ment (30 min), or placement on a vibrating/rocking platform (1 h).
Animals were then subjected to a first behavioral testing (see below)
before receiving intracerebroventricular infusions of either freshly solu-
bilized A1-40 or vehicle (see below) over 14 d. Subgroups of animals
received subcutaneous GC injections [dexamethasone, 300 g/ml/kg
BWdelivered in an oily suspension (depot) (1:10 Fortecortin, (Merck) in
sesame oil (Sigma)] for 14 d. Animals were subjected to a second behav-
ioral test at the end of the various treatments. Efficacy of the stress para-
digm was verified at autopsy: basal serum corticosterone levels were
54.7 4.8 and 384.6 65.9 ng/ml, respectively, in control and stressed
rats ( p 0.02); net bodymass gain/losswas12.1 2.1 g in stressed rats
and6.1 1.3 g in control animals ( p 0.0001); thymus weights were
4.3 0.4mg/kg BW in stressed animals and 7.6 0.9mg/kg BW control
animals ( p 0.01).
Intracerebral infusions. Alzet miniosmotic pumps (delivering 0.5 l/h
over 14 d;model 2002, Charles River), filled and equilibrated with 4.2 nM
A1-40 (AmericanPeptide) or vehicle (sterile distilledwater), were placed
subcutaneously under anesthetic. Alzet Brain Infusion sets were used to
connect the outlet of the pumps to a cannula placed under stereotaxic
control into a left lateral ventricle of the brain (stereotaxic coordi-
nates: anteroposterior, 1.0 mm; dorsoventral, 2.5 mm; and medio-
lateral,1.5mm (right) with bregma as a reference, under pentobarbital
(50 mg/kg) anesthesia. We infused A1-40 rather than the more patho-
genic A1-42 species because the former aggregates less readily (Harper et
al., 1997). None of the biometric parameters were significantly altered by
the A1-40 infusions.
Behavioral tests. Spatial reference memory was tested using theMorris
water maze over 4 consecutive days (4 trials per day). As previously
described (Cerqueira et al., 2007), testing was conducted in a circular
black tank (170 cmdiameter) filled to a depth of 31 cmwith opaquewater
(22°C) and placed in a dimly lit room with extrinsic clues. The tank was
divided into virtual quadrants and had a black platform (12 cmdiameter,
at a height of 30 cm) placed in one of them. Data were collected using a
video tracking system (Viewpoint). Assessment of reversal learning (four
trial paradigm) was begun 1 d later using the above setup. For this, the
escape platform was repositioned in the opposite (new) quadrant; and
rats were tested in a four trial paradigm (1 trial per day), with distance
and time spent swimming in each quadrant being recorded.
Immunocytochemistry. Half of each brain was used for immunohisto-
chemical analysis; hippocampi and PFCs from the contralateral sidewere
processed for Western blotting. Brains excised at autopsy were snap fro-
zen, post-fixed in 4% paraformaldehyde, immersion fixed for 48 h, par-
affin embedded, and sectioned at 8 m. Following antigen retrieval
(microwaved in sodium citrate, 30 min), washing (TBS), and blocking
endogenous peroxides with H2O2 (3%), slide-mounted sections were
incubated in an appropriate nonimmune serum (1:10 in TBS, pH 7.6, 30
min). Sections were then incubated [room temperature (RT) overnight]
with primary antibodies of interest [Tau-5 (1:200), CP-13, PHF1, PG5
(all at 1:50), and 12E8 (1:100)] before washing and incubation with
biotinylated secondary antibody (BioGenex) (RT, 30 min.) After a fur-
ther wash in TBS, slides were incubated (30 min, RT) with a horseradish
peroxidase complex (BioGenex). Immunopositive structures were re-
vealedwith the chromogen diaminobenzidine (1mg/ml in 0.01%H2O2);
stain development wasmonitored using amicroscope. Negative controls
were performed by omitting the primary antibody (no staining was seen
in any sections). Staining was scored by visual examination on a scale of
0.5–5 by an independent investigator who was blind to the treatments. The
degree of antibody staining was scored by visual examination on a scale of
0.5–5 by two independent subjects who were blind to the treatments.
Western blotting. Frozen hippocampi and PFC were homogenized in
lysis buffer [100mM Tris-HCl, 250mMNaCl, 1 mM EDTA, 5mMMgCl2,
1% NP-40, Complete Protease Inhibitor (Roche), and Phosphatase In-
hibitor Cocktails I and II (Sigma)] using a Dounce glass homogenizer;
extracts were cleared by centrifugation (14,000  g), and their protein
contents were estimated (Lowry assay) after reconstitution in Laemmli
Figure 1. Chronic stress upregulates the expression of various phospho-TAU epitopes and
TAU kinases. a, b, Depicted are representative immunoblots using a panel of phosphorylation-
dependent TAU antibodies (a) and total and active isoforms of kinases (b).
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buffer (250 mM Tris-HCl, pH 6.8, containing
4%SDS, 10%glycerol, 2%b-mercaptoethanol,
and 0.002% bromophenol blue). Thereafter,
lysates were electrophoresed on 10% acryl-
amide gels, and transferred onto nitrocellulose
membranes (Protran BA 85, Schleicher &
Schuell). Membranes were blocked in Tris-
buffered saline containing 5% nonfat milk
powder and 0.2% Tween-20 before incubation
with the following antibodies: Tau-5 (1:200,
BD Biosciences), CP-13 (p-Ser202-Tau), CP-9
(p-Thr231-Tau), PHF1 (p-Ser396/404-Tau),
or PG5 (p-Ser409-Tau), all kindly providedDr.
Peter Davies (Albert Einstein College of Medi-
cine, New York, NY) and used at a dilution of
1:50, total and p-Thr202/204 ERK1/2 (1:2500,
Cell Signaling Technology), total and
p-Thr183/Tyr185 JNK (1:1000, Cell Signaling
Technology), cdk5 (1:1000, Millipore), p35
(Santa Cruz Biotechnology), GSK3 (1:2000,
Santa Cruz Biotechnology), p-Tyr216/279
GSK3 (1:2000, Biosource), CaMKII (1:1000,
Cell Signaling Technology ), and actin (1:2000,
Millipore). Antigens were revealed by en-
hanced chemiluminescence (GE Healthcare)
after incubation with appropriate horseradish
peroxidase–IgG conjugates (GE Healthcare);
blots were scanned and quantified using TINA
3.0 bioimaging software (Raytest) after ascertain-
ing linearity. All values were normalized and ex-
pressed as percentages of control.
Detection of detergent-insoluble TAU. Sarkosyl-
insoluble fractions from tissue protein extracts
werepreparedaspreviouslydescribed(Kimuraet
al., 2010). Briefly, frozen hippocampi of P301L
tau mice were homogenized in Tris-buffered sa-
line (10mMTris, 150mMNaCl, pH7.4) contain-
ing protease inhibitors (1 mg/ml antipain, 5
mg/ml pepstatin, 5 mg/ml leupeptin, 2 mg/ml
aprotinin, and 0.5 mM 4-[2-aminoethyl]benze-
nesulfonyl fluoridehydrochloride) andphospha-
tase inhibitors (1 mMNaF, 0.4 mMNa3VO4, and
0.5 mM okadaic acid). After centrifugation, the
supernatantwas retained andSarkosyl-insoluble,
paired helical filament-enriched fractions were
prepared from TBS-insoluble pellets after reho-
mogenization in 5 volumes of sucrose buffer (0.8
MNaCl, 10% sucrose solution including protease
and phosphatases inhibitors as mentioned
above) and centrifugation (100,000 g, 20min).
Sarkosyl (10%) was added to the supernatant
(1:10 v/v), and, after incubation at 37°C (1h) and
centrifugation (150,000  g, 1 h), the resulting
pellet was considered as the Sarkosyl-insoluble fraction. TBS-soluble and
Sarkosyl-insolublematerials were solubilized in Laemmli sample buffer and
subjected to SDS-PAGE and Western blot analysis using rabbit polyclonal
anti-TAU (phosphorylated and nonphosphorylated isoforms) as described
previously (Kimura et al., 2010).
Statistical analysis.With the exceptionof the referencememory test data
(repeated-measures ANOVA), all data were evaluated by one-way
ANOVA and appropriate post hoc pairwise tests using SPSS and SigmaS-
tat (Systat) software packages; differences were considered to be signifi-
cant if p 0.05.
Results
Chronic stress and GC induce abnormal
hyperphosphorylation of TAU
Abnormal hyperphosphorylation of tau is a critical event in the
cascade leading to AD pathology (Grundke-Iqbal et al., 1986; Sch-
neider et al., 1999; Kimura et al., 2007). Clinical reports of GC
hypersecretion in AD patients and in cases of mild cognitive im-
pairment, a condition with a high conversion rate to AD (Hart-
mann et al., 1997; Weiner et al., 1997; Elgh et al., 2006; Wilson et
al., 2007), prompted us to examine how elevated GC secretion,
induced by chronic unpredictable stress, influences the pattern of
tau phosphorylation in the hippocampus and PFC, brain regions
that are established targets of the deleteriousmorphological and be-
havioral actions of stress andGC (Sousa et al., 2000; Cerqueira et al.,
2007; Schubert et al., 2008; Sotiropoulos et al., 2008a)andamong the
first to show signs of AD neuropathology (Lace et al., 2009).
Immunoblot analysis showed that chronic stress results in
hyperphosphorylation of TAU at pSer202, pThr231, pSer396/
404, and pSer409 in both brain regions of interest ( p 0.05 in all
cases) (Figs. 1, 2a,b); immunocytochemical confirmation of these
Figure 2. Stress and GCs induce TAU hyperphosphorylation in the hippocampus and PFC. TAU phosphorylation profiles in the
hippocampus and PFC of chronically stressed or GC-treated rats were monitored by Western immunoblotting and immunocyto-
chemistry.a,b,Western blot analysis of TAU phosphorylation at different epitopes in hippocampus and PFC. TAU phosphorylation
levels were normalized against total TAU levels (recognized by TAU-5); control (CON) animals are shown as dotted lines (100%). c,
d, Immunohistochemical staining of pSer202-TAU and pSer262/356-TAU, in the hippocampus (subiculum) and PFC, using anti-
bodies CP-13 and 12E8 antibodies, respectively. Immunoreactive signals were confined to the cell bodies of pyramidal neurons. e,
f, Both stress and GCs increased the expression of a number of kinases in the hippocampus and PFC of animals exposed to stress or
GC, compared with controls. For all phosphorylated forms of kinases, data were normalized with respect to total levels of the
respective kinase. g, Western blot analysis of sarkosyl-insoluble fractions from P301L-TAU animals showing that chronic stress
increases the levels of sarcosyl-insoluble TAU. All numerical data shown represent mean SEM values (N 7), depicted with
respect to data obtained in control tissues. *Significant differences from CON values ( p 0.05).
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results using the phosphorylation-dependent antibodies CP13
(pSer202-TAU) and12E8 (pSer262/Ser356-TAU) are shown for the
subiculum (Fig. 2c) and PFC (Fig. 2d). Importantly, administration
of exogenous GC to nonstressed animals largely reproduced the ef-
fects of chronic stress ( p 0.05 in all cases) (Figs. 1, 2a,b). In addi-
tion tomonitoringTAUphosphorylationprofiles,wealsoexamined
several kinases implicated in TAU pathology associated with AD
(Mazanetz et al., 2007). As shown in Figures 1 and 2, e and f, stress
and/or GC activated pERK1/2, pGSK3, p35 (the cdk5 activator),
pJNK, and CaMKII in the hippocampus and PFC ( p 0.05). To-
gether, these results show that stress and GC promote a pattern of
changes that closely resemblesneuropathological findings inADand
in cellular and animal models of the disease
(Green et al., 2006; Jeong et al., 2006 Sotiro-
poulos et al., 2008b).
Since the expression of hyperphospho-
rylatedTAUspecies correlateswith thepres-
ence of insoluble TAU aggregates in AD
brains (Wang et al., 1995; Alonso et al.,
2001;Maeda et al., 2006),wenext examined
whether stress influences the aggregation of
TAU. To that end, Sarkosyl-insoluble TAU
was extracted from the brains of aggrega-
tion-prone P301L-Tau transgenic mice
(Kimura et al., 2010) and analyzed byWest-
ern blotting. Expectedly (Kimura et al.,
2010), brains fromP301L-Taumice showed
detectable levels of detergent-insoluble
TAU immunoreactivity; the latter was sig-
nificantly increased in extracts fromP301L-
Tau mice that had been previously exposed
to stress (Fig. 2g). These results indicate that
stress aggravates TAU aggregation.
Potentiating effects of glucocorticoids
GCs were recently shown to stimulate the
generation of A in experimental animals
(Green et al., 2006; Jeong et al., 2006; Ca-
tania et al., 2009) and neural cell cultures
(Sotiropoulos et al., 2008b) and to poten-
tiate the deleterious effects of A on neu-
ronal survival (Sotiropoulos et al., 2008b).
Demonstrations that GCs trigger hyper-
phosphorylation of TAU in neuronal cul-
tures (Sotiropoulos et al., 2008b) raised
the question of whether this is also the
case in vivo. We addressed this by moni-
toring the expression of pathogenically
relevant phospho-TAU epitopes (Augus-
tinack et al., 2002; Ewers et al., 2007; van
der Vlies et al., 2009) in a nontransgenic
rat model of early-stage AD (Ste´phan and
Phillips, 2005).
Chronic intracerebroventricular infu-
sionsofA led toa significant increase in the
expression of the majority of tested phos-
phorylated sites of tau protein in the hip-
pocampus and PFC ( p 0.05) (Fig. 3a,b),
indicating tau hyperphosphorylation at dif-
ferent sites. These effects were potentiated
by concomitant treatmentwithGCs, inpar-
ticular with respect to pSer202-TAU in the
hippocampus (Fig. 3a,c) and PFC (Fig. 3b),
pSer396/404- and pSer409-TAU in the hip-
pocampus (Fig. 3a), and pSer262/356 in the PFC (Fig. 3d). In addi-
tion, the combined treatment of GC and A resulted in increased
pSer396/404-TAUstainingof thehippocampalmossy fiber network
(GCA A alone) (Fig. 3e). Correspondingly, compared with
A alone, the combinedA andGC treatment regimen resulted in a
greater upregulation of hippocampal levels of activated ERK1/2,
pJNK, and pGSK3 ( p 0.05 in all cases) (Fig. 3f).
History of stress increases sensitivity to GC and A
Individuals experiencemultiple lifetime stressors, usually with an
amplification of the GC response to successive stressful episodes
Figure 3. GCs potentiate A-induced TAU hyperphosphorylation. a, b, Concomitant administration of A and GCs resulted in
increases in the levels of several phospho-TAU isoforms in the rat hippocampus (a) and PFC (b), as measured byWestern blotting;
these increaseswere greater than after treatmentwith A alone ( †p 0.05). Note the differential responses of the hippocampus
and PFC in terms of number of phospho-TAU epitopes that were affected by the combined A GC treatment. c, d, Immunocy-
tochemical analysis of pSer202-TAU (detected with antibody CP13; c) and pSer262/356-TAU (antibody 12E8; d) in hippocampus
(subiculum) and PFC confirmed the aboveWestern blot analysis data. e, Illustration of pSer396/404-TAU staining (using antibody
PHF-1) in the mossy fiber system of control rats and rats treated with A or A GCs. While CP-13 and 12E8 immunoreactivity
was localized to neuronal perikarya, that of PHF-1 was predominantly found within mossy fibers. f, Significant increases in the
expression of pERK1/2, pJNK and pGSK3 levels were observed in the hippocampus. Note that total levels of the respective TAU
kinases were not altered by any of the treatments. Numerical data represent mean  SEM values (N  7), depicted after
normalization to total Tau (a,b) or respective total kinases (f,g). *Significant differences fromCONvalues ( p0.05); †significant
difference ( p 0.05) between corresponding pairs of values for each treatment group (A vs A GC).
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(Lupien et al., 2009). In an attempt to sim-
ulate this natural situation, middle-aged
rats were subjected to chronic stress be-
fore receiving intracerebroventricular in-
fusions of A and/or peripheral GC
injections.
Compared with animals that received
A alone, those receiving the combinatorial
treatment of A and GC showed an en-
hancement of phosphorylation of several
TAU sites (pSer202, pSer396/404, pThr231,
pSer409) in thePFCandhippocampus (Fig.
4a,b), with parallel increases in pERK1/2,
pJNK, and pGSK3 (Fig. 4c,d) expression.
In agreement with these findings, stressed
animals that were subsequently treatedwith
A and GC displayed more intense immu-
nostainingofPHF-1 (pSer396/404-TAU) in
hippocampal neurons comparedwith those
treated with A alone (Fig. 4e). Further-
more, GC led to a greater accumulation of
hyperphosphorylated TAU in the perikarya
of hippocampal (compare Figs. 4e, 3e) and
PFC (Fig. 4f) neurons of previously stressed
animals (stress  GC  A  GC A);
these findings are supportedby the observa-
tion of graded increases in the level of total
neuronal TAU detected with pan-TAU
(TAU-5) antiserum (Table 1).
Behavioral profiles
There is a strong correlation between the
extent of TAU hyperphosphorylation and
the severity of impairments of memory,
speed of mental processing, and executive
functions in humans (Augustinack et al.,
2002; Ewers et al., 2007; Lace et al., 2009);
in experimental animals, learning and
memory are impaired when TAU is hy-
perphosphorylated (Gatz et al., 2006;
Kimura et al., 2007).
Consistent with previous findings
(Sousa et al., 2000; Cerqueira et al., 2007),
tests ofhippocampus-dependent spatial ref-
erence memory and PFC-dependent rever-
sal learning showed that both stress andGC
disturbed hippocampus-dependent refer-
ence memory ( p  0.05) (Fig. 5a,b) and
PFC-dependent behavioral flexibility ( p 0.05) (Fig. 5c,d). Central
infusions of A significantly impaired reference memory ( p 
0.001) (Fig. 5a), an effect aggravated by coadministration of GC. As
is evident from Figure 5b, even more pronounced impairments of
referencememory were observed when A and GCwere applied to
animals that had been previously exposed to stress (stress A vs
stressAGC, p 0.0001). Behavioral flexibility was impaired
by centrally applied A ( p 0.001) (Fig. 5c). Interestingly, super-
imposition of GC did not worsen this PFC-dependent behavioral
parameter (Fig. 5c),matching the lackof changes inTAUphosphor-
ylation in the PFC after the combined treatment (Fig. 2b). On the
other hand, GC significantly exacerbated this PFC-dependent be-
havioral deficit in previously stressed animals ( p  0.05 (Fig. 4d).
Together with the data on the hyperphosphorylation and accumu-
lationofTAU(compareFigs. 3, 4) (Table 1), these findingshighlight
the cumulative and deleterious effects of stress/GCs.
Discussion
Environmental factors account for 25–40%of the risk of developing
AD (Gatz et al., 2006), a disease that develops progressively over
decades. Stress, whose effects are mediated by GCs, is a plausible
causal agent (Wilson et al., 2003; Csernansky et al., 2006; Kang et al.,
2007). Clinical studies show a relationship between GC levels and
severity of symptoms (Miller et al., 1998) and suggest that high GC
levels accelerate disease progression (Csernansky et al., 2006).
The present study in rats delivers new insights into the link
between stress and AD. Our results show that stress induces a
biochemical anomaly found in AD, namely, hyperphosphoryla-
tion of themicrotubule protein TAU; importantly, at least two of
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Figure 4. Previous stressful experience increases sensitivity to A GC. a–d, Animals that had experienced chronic unpre-
dictable stress (1 month) responded to cotreatment with dexamethasone GCs, 300 g/kg BW/d) and A (0.3 nmol/d) with
increases in TAU phosphorylation (a, b) and levels of TAU-related kinases (c, d); overall, stressed animals exhibited higher suscep-
tibility to the combinatorial treatment than nonstressed animals. Immunoblotting revealed that, in contrast to the hippocampus,
the PFC of previously stressed animals show a greater extent of TAU hyperphosphorylation (compare Fig. 2b) and expression of
active forms of ERK1/2 and JNK (compare Figs. 4c,d, 3f,g) after treatment with GC A, indicating the cumulative nature and
dissipation of the effects of stress and GCs from the hippocampus to the PFC. e, Immunohistochemical analysis demonstrated an
enhancement of PHF-1 immunoreactivity in themossy fiber network of thehippocampusof stressed rats receivingAorAGC
(A GC A vehicle). f, Strong PHF-1 immunoreactivity is shown in the perikarya of PFC neurons of stressed A
GC-treated rats (micrograph of the PFC region from a nonstressed rat that had been treatedwith A GC is shown in panel f, for
comparison). Insets in f are high-power magnifications of the rectangular areas marked in the respective low-magnification
micrographs. All numerical data shown represent mean SEM values (N 6–7), depicted with respect to data obtained in
control tissues (CON, dotted line), set at 100%. *Significant differences fromCON values ( p 0.05); †Significant difference ( p
0.05) between corresponding pairs of values for each treatment group (stress A vs stress A GC).
7844 • J. Neurosci., May 25, 2011 • 31(21):7840–7847 Sotiropoulos et al. • Chronic Stress and Tau Malfunction
the phospho-TAU epitopes (pThr231 and pSer262) upregulated
by stress are strongly implicated in the neuropathology of AD
(Grundke-Iqbal et al., 1986; Sengupta et al., 1998; Kimura et al.,
2007; Mazanetz and Fischer, 2007; Wang et al., 2007; Sotiropou-
los et al., 2008b). Hyperphosphorylation of Thr231- and Ser262-
TAU disrupts microtubule stability and leads to retrograde
neuronal degeneration and synaptic loss; moreover, strong asso-
ciations between increased levels of pThr231 and pSer262 and the
appearance of neurofibrillary tangles have been reported previ-
ously (Sengupta et al., 1998; Schneider et al., 1999; Alonso Adel et
al., 2006; Kimura et al., 2007; Mazanetz and Fischer, 2007). We
here found that administration of exogenousGCs tomiddle-aged
rats partly recapitulates the effects of stress on TAU hyperphos-
phorylation. Although specific TAU phosphoepitopes were differ-
entially regulated by stress andGCs, the overall results obtainedhere
and in earlier in vitro studies (Sotiropoulos et al., 2008b) clearly
implicate GCs as a key mediator of the cellular response to stress.
Nevertheless, contributionsbyother stress-relatedmolecules suchas
corticotrophin-releasing hormone cannot be excluded (Rissman et
al., 2007), andpossible interactionsbetweenGCandcatecholamines
cannot bedismissed since stress stimulates the release of central nor-
epinephrine (Nisenbaumet al., 1991). Understanding these interac-
tions would be important given that TAU hyperphosphorylation
and pathology is triggered bymisprocessing of APP into A and/or
C99 (Takashima et al., 1998;Ghosal et al., 2009, Shipton et al., 2011)
and that norepinephrine can reduce A pathology (Heneka et al.,
2010).Notwithstanding likely “ceiling effects” of the treatments (for
the case ofGC, seeGreen et al., 2006), physiological regulatory loops
might also underpin our observations that the magnitude of effects
of the combined treatments (e.g., stress and A  GC) on TAU
pathology are not merely additive.
The present finding that stress and GCs increase TAU hyper-
phosphorylation and accumulation inneuronal soma largely echoes
and extends previous reports in AD transgenicmodels (Green et al.,
2006; Jeong et al., 2006) and neuronal cell cultures (Sotiropoulos et
al., 2008b). Specifically, our results show that stress/GCs induce ex-
tensive hyperphosphorylation of TAU at more epitopes (several
considered critical inAD) thanweredescribedby Jeong et al. (2006);
further, we show that stress aggravates the aggregation of Sarkosyl-
insoluble TAU.Detergent-insoluble TAUaggregates eventually give
rise to the neurofibrillary tangles characteristic of tauopathies, in-
cluding AD (Wang et al., 1995; Kimura et al., 1996; Alonso et al.,
2001); moreover, insoluble TAU and TAU oligomers are causally
implicated in neurodegenerative processes (Berger et al., 2007) and
Figure 6. Workingmodel of howstress acts cumulatively to induce TAUpathology and cognitive
impairment. Repeated exposures to adverse life events (stress), accompanied by increased levels of
GCs, induceTAUpathologyinacumulativemanner.TAUhyperphosphorylationisprobablystimulated
secondarily to stress/GC-inducedmisprocessingofAPP toamyloidogenic peptides suchas amyloid
andC99 (Sotiropoulosetal., 2008a;Cataniaetal., 2009).HyperphosphorylatedTAUaccumulatesand
aggregates inneuronalperikarya, leading toneuronaldystrophyanddysfunction. The firstdetrimen-
tal signs of stress are seen in the hippocampal and parahippocampal regions, gradually spreading to
the PFC and other cortical regions; similar spatiotemporal patterns are observed in patients with
Alzheimer’s disease (Lace et al., 2009). Rat brain imageswere adapted fromSwanson (1999).
Table 1. Relative amounts of TAU staining in the hippocampus (CA3 subfield) and
PFC of control and stressed animals treated with either vehicle, A or A and GC
Hippocampal CA3 PFC
Control
Vehicle  
A  
A GCs  
Stress
Vehicle  
A  
A GCs  
Total TAUwas detected using TAU-5, and scoreswere assigned by an observerwhowas blind to the treatments.,
Very low;, low;, moderate;, high;, very high.
Figure 5. Stress exacerbates the cognition-impairing actions of A and GC. a–d,
Hippocampus-dependent spatial reference memory (a, b) and PFC-dependent working mem-
ory (reversal learning used to measure behavioral flexibility) (c, d) in nonstressed (a, c; N 7)
and stressed (b, d; N 6) rats. Chronic, unpredictable stress (1 month) was imposed before
subgroups of animals were treated with either vehicle, A or AGC for 14 d. A1-40 was
chronically infused into the lateral ventricle at a dose of 0.3 nmol/d; dexamethasone (GC) was
given as a daily depot injection at a dose of 300 g/kg, s.c. In nonstressed animals, spatial
referencememorywas impaired after A treatment ( p 0.001), and concomitant GC admin-
istration resulted in slight worsening of the deficit (a). While treatment with A alone did not
interfere with spatial memory in previously stressed rats, combined treatment with A and GC
markedly impaired spatial memory ( p 0.0001) (b). Compared with their nonstressed coun-
terparts, stressed rats showed deficits in workingmemory ( p 0.05), as revealed by compar-
ison of percentage distance swum in the new (W) and old (E) quadrant of the maze (c, d).
Treatment of nonstressed ratswith A reduced performance in the reversal learning test ( p
0.05), an effect that was not changed in GC A-treated animals (c). In contrast, although
reversal learning was not disrupted after administration of A alone to previously stressed
animals, the behavior was significantly impoverished in stressed animals that were subse-
quently given the combined A GC regimen ( p 0.05) (d). *Significant differences from
CON values; †significant difference between stressed and nonstressed animals.
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are foundduring presymptomatic stages of AD (Maeda et al., 2006).
The discrepancy between our results (stress/GC-induced TAU hy-
perphosphorylation) and those of Green et al. (2006)may be attrib-
uted to the fact that the latter authorsused3Tgmice expressing the
P301-mutated TAU; wild-type TAU and P301L-mutated TAU dis-
play distinct phosphorylation profiles and exert dissimilar effects on
neuronal structure and function (Kimura et al., 2010) and may be
differentially regulated by stress. Further, Green et al. (2006) studied
whole-brain homogenates, whereas our analysis in wild-type ani-
mals focused on specific brain regions that are affected in AD and
targeted by stress/GCs.
Dendritic andsynaptic atrophy, aswell as cognitive impairments,
are well known consequences of chronic stress and the accompany-
ing increases in GC secretion (Sousa et al., 2000; Cerqueira et al.,
2007; Landfield et al., 2007; Schubert et al., 2008; Lupien et al., 2009),
albeit through still poorly understood cellularmechanisms. Extend-
ing earlier reports on the deleterious effects of GCs on cytoskeletal
proteins, including TAU (Stein-Behrens et al., 1994; Cereseto et al.,
2006), the results of the present study demonstrate that stress and
GCs induce TAU hyperphosphorylation at epitopes implicated in
cytoskeletal pathology and synaptic loss in AD patients (e.g.,
pSer262) (Callahan et al., 2002; Lauckner et al., 2003) and correlated
with hippocampal atrophy in AD patients (e.g., pThr231) (Hampel
et al., 2005). Clinical studies report a strong correlation between the
extent of TAU hyperphosphorylation (including that of the Thr231
and Ser262 residues) and severity of impairments ofmemory, speed
of mental processing, and executive functions (Augustinack et al.,
2002, Ewers et al., 2007; van der Vlies et al., 2009). In addition, TAU
hyperphosphorylation is associated with synaptic loss and memory
impairment in experimental animals (Kimura et al., 2007). Basedon
the above considerations, we suggest that TAU hyperphosphoryla-
tion might be part of the cellular mechanism through which stress
and GCs cause dendritic and synaptic dysfunction. In this connec-
tion, it is relevant to mention that recently Hoover et al. (2010)
showed that hyperphosphorylated TAU within dendritic spines in-
duces synaptic abnormalities,while Ittner et al. (2010)demonstrated
that TAU mediates the synaptotoxic actions of A. Results of the
present study, together with other reports that TAU is essential for
the manifestation of the actions of A (Busciglio et al., 1995; Rapo-
port et al., 2002; Roberson et al., 2007; Shipton et al., 2011) and our
previous demonstrations that stress and GCs trigger APP mispro-
cessing in animals (Catania et al., 2009) andneuronal cultures (Soti-
ropoulos et al., 2008b), provide a mechanistic sequence through
which stress leads to the expression of AD-relevant biochemical and
behavioral markers. Accordingly, A and TAU are introduced as
new players in the cascade of events responsible for stress-induced
brain dysfunction.
There is growing consensus that stress renders individuals vul-
nerable to brain disorders by causing inappropriate remodeling
of individual neurons and disconnection of critical neural cir-
cuits (Cerqueira et al., 2007; Sotiropoulos et al., 2008a). The re-
sults reported here show that animals with a history of stress are
more sensitive to the deleterious actions of A and GCs; more-
over, previously stressed animals express higher levels of hyper-
phosphorylated TAU and display more overt signs of memory
dysfunction. Thus, previous stressful experiences may leave a
“trace of vulnerability” to the development of AD-like pathology,
with vulnerability increasingwith age (Sotiropoulos et al., 2008a). In
addition, our findings that GCs and stress act cumulatively suggest
that repeated adverse experiences over an individual’s lifetime will
increase the probability or severity of AD pathology (Fig. 6). Our
demonstration that stress and GCs can induce TAU pathology in
otherwise healthy, middle-aged nontransgenic animals reinforces
the view that lifetime experiencemay be an etiological factor in spo-
radic forms of AD. In this respect, the growing body of evidence for
epigenetic regulation of ADpathophysiology (for review, see Chou-
liaras et al., 2010) isworthnoting. Last, the introductionofTAUinto
the cascade of events leading to stress-induced neuronal and behav-
ioral dysfunction has implications that extend beyond AD itself:
stress is considered to be a major trigger of major depression, a dis-
ease that places individuals at a significant risk for developing AD
(Ownby et al., 2006; Sun et al., 2008).
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